Illumina Oncology - Testing for 𝘕𝘛𝘙𝘒 fusions

14 November 2022

Vivek Subbiah, MD, explains how patients with rare and common tumors can benefit from next generation sequencing-based testing for _NTRK_ gene fusions. He presents the case of a patient who benefited from precision medicine based on the detection of a _NTRK1_ fusion by comprehensive genomic profiling. Vivek Subbiah, MD is the Medical Director of the Clinical Center for Targeted Therapy and Executive Director of Oncology Research at the University of Texas MD Anderson Cancer Network. Listen to the podcast episode to learn more about when to test for _NTRK_ fusions: Learn about Homologous Recombination Deficiency (HRD) testing in ovarian cancer: The Illumina Oncology series is brought to you by Medical Affairs. M-GL-01113 Subscribe to the Illumina video channel A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos View Illumina webinars View Illumina product videos View Illumina support videos

Share this article on